INVESTORS AREAInformation for investors
Vytrus Biotech receives valuation of 26.4 million euros according to GVC Gaesco
The biotechnology company has received a valuation report from GVC Gaesco Valores, which estimates a target price of 3.71€/share December 2023e for the company, equivalent to 26.4 million euros, 10% more than yesterday's closing price.
Vytrus registers its first patent in Europe, USA and Japan for hair loss
Europe, USA and Japan have granted the Spanish stock market-listed company with a patent in the field of hair loss prevention and treatment, framed within the proprietary firm’s biotechnology platform called Phyto-Peptidic Fractions. Through this platform, Vytrus has developed several active ingredients from plant stem cells for applications in skincare and haircare.
Silver Best Ingredient Award for Vytrus at in-cosmetics Asia 2022
Vytrus Biotech has been awarded with the Silver Best Ingredient Award for its natural active ELAYA RENOVA™ at in-cosmetics Asia 2022, the leading event for personal care ingredients in the region.
Vytrus Biotech increases its sales by 51% in the first half of 2022
The company has closed the first half of 2022 with a turnover of 2.04 million euros, a record for the firm, and gross operating profit (Ebitda) of 860 thousand, 62% more than in the same period of the previous year, as reported to the market.
Vytrus awarded first position at Cosmetorium Awards 2022
The biotech company has been awarded with the first position at Cosmetorium 2022 for its innovation with a cosmetic formulation containing QUORA NONI™ biomics, a new ingredient that rejuvenates the skin microbiota to achieve a younger-looking skin.
Gold Best Ingredient Award for Vytrus at in-cosmetics Latin America 2022
Vytrus Biotech has been awarded with the Gold Best Ingredient Award for its natural active ELAYA RENOVA™ at in-cosmetics Latin America 2022, the leading event for personal care ingredients in the region.
First position at BBVA Sustainable Innovation Award for Vytrus
Vytrus Biotech has been recognized with the first position at BBVA Award to the Innovation in Environmental Sustainability for its environmentally friendly business model.
Vytrus increases its net profit by more than 100% in 2021
The biotechnology company has closed 2021 financial year with the best results in its history by rising its net profit by 100%. Vytrus also increased its market value by 100% in its first trading month.
Vytrus rises more than 25% in its stock market debut on March 15th
Vytrus Biotech has been listed in BME Growth and increases its market value by more than 25% in its first trading day.
Vytrus announces its intention to be listed in BME Growth and a 65% sales increase
The biotechnology company is finalizing the procedures for its launch on the alternative stock market (BME Growth) in the coming months.
Vytrus increases its sales by 40% and triples its EBITDA in 2020
Vytrus has broken its own record and sales forecasts, reaching 1.7 million euros at the end of 2020, while increasing its EBITDA by 200% in the same period.
Vytrus Biotech raises €1.7M and turns into an industrial company
The Spanish company, specialised in active ingredients for the cosmetic sector, reaches €1.22M on sales and expects to increase its turnover by 23% in 2020